| Budesonide |
Capsule |
II (Paddle) with sinker |
75 |
Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 7.5 |
Acid stage: 1000; Buffer stage: 1000 |
Acid stage: 2 hours; Buffer stage: 0.25, 0.5, 1, 2, 4, 6 and 8 hours |
2015/02/25 |
| Budesonide |
Tablet (Extended Release) |
II (Paddle) |
100 |
Acid Stage: 0.1 M HCl containing
0.5% Macrogol Cetostearyl Ether; Buffer Stage: pH 7.2 phosphate buffer containing 0.5% Macrogol
Cetostearyl Ether. |
Acid Stage: 500 mL ; Buffer Stage: 1000 mL |
Acid Stage: 2 hours; Buffer Stage: 1, 2, 4, 6, 8 and 10 hours |
2015/04/02 |
| Bumetanide |
Tablet |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Bupivacaine |
Solution (Extended Release), Infiltration |
II (Paddle) |
50 |
0.025 M Sodium Phosphate Buffer with 0.03% Sodium Dodecyl Sulfate (SDS), pH 7.4 |
900 |
1, 2, 4, 8, 12, 16, 24, 36 and 48 hours |
2022/07/07 |
| Bupivacaine; Meloxicam |
Solution, Extended Release |
|
|
Develop a method to characterize in vitro release |
|
|
2025/09/08 |
| Buprenorphine |
Film, Transdermal (Extended Release) |
VI (Cylinder) with adapter, if needed |
50 |
0.9% Sodium Chloride at 32°C |
600 |
0.5,1, 2, 4, 6, 8,12, 16 and 24 hours |
2013/05/09 |
| Buprenorphine HCl |
Implant |
II (Paddle) |
50 |
Water |
900 |
1, 4, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours |
2016/07/28 |
| Buprenorphine HCl |
Film (Buccal) |
I (Basket) 100 mL round bottom vessel |
100 |
0.05M NaH2PO4.H2O Phosphate Buffer, pH 4.5 |
60 |
10, 15, 20, 30, 45 and 60 |
2016/10/20 |
| Buprenorphine HCl |
Tablet (Sublingual) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Buprenorphine HCl/Naloxone HCl |
Tablet (Sublingual) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Buprenorphine HCl/Naloxone HCl |
Film (Sublingual) |
V (Paddle over Disk) with 56 mm, 40 mesh stainless steel disk. |
100 |
Acetate Buffer, pH 4.0 (12.5mM Sodium acetate trihydrate and 60mM glacial acetic acid. Adjust the pH with glacial acetic acid or ammonium hydroxide). |
900 |
1, 2, 3, 5, 7 and 10 |
2013/10/31 |
| Bupropion HCl |
Tablet (Extended Release) |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Bupropion HCl |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Bupropion Hydrobromide |
Tablet (Extended Release) |
I (Basket) |
75 |
0.1 N HCl |
900 |
1, 2, 4, 6, 8 and 10 hours |
2009/06/10 |
| Buspirone Hydrochloride |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Buspirone Hydrochloride |
Capsule |
II (Paddle) |
50 |
0.01 N HCl |
500 |
10, 20, 30 and 45 |
2024/11/01 |
| Busulfan |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Busulfan |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Cabergoline |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Cabotegravir |
Suspension (Extended Release) |
II (Paddle) |
20 |
0.5% w/v cetyltrimethylammonium bromide (CTAB) in 140 mM McIlvaine buffer, pH 7.4 |
1000 |
5, 10, 20, 30, 45 and 60 |
2023/07/07 |